Develops glycoengineered bioconjugate vaccines targeting pneumococcal pneumonia, utilizing patented conjugating enzyme technology for streamlined production and broader serotype coverage. The approach enhances vaccine efficacy and opens pathways for combating other bacterial pathogens.